ContributorsPublishersAdvertisers

CAR T-cell Therapy in Relapsed/Refractory Mantle Cell Lymphoma

onclive.com
 2022-01-21

Cover picture for the articleBijal D. Shah, MD, MS: This is a perfect segue to CAR [chimeric antigen receptor] T-cell therapy. Caron, you were part of a real-world consortium data set looking at CAR T. Now, when CAR T was first studied on the ZUMA-2 clinical trial, it was for BTKi [Bruton tyrosine kinase inhibitor]...

www.onclive.com

Comments / 0

Comments / 0